Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine

Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine

With the emergence of immune checkpoint inhibitors and adoptive T-cell therapies, there is a considerable interest in using personalized autologous dendritic cell (DC) vaccines in combination with T cell-targeting immunotherapies to potentially maximize the therapeutic impact of DC vaccines. Here, w...

Full description

Bibliographic Details
Main Authors: Caroline Boudousquié, Valérie Boand, Emilie Lingre, Laeticia Dutoit, Klara Balint, Maxime Danilo, Alexandre Harari, Philippe O. Gannon, Lana E. Kandalaft
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Vaccines
Subjects:
immunotherapy
dendritic cell
vaccine
manufacturing
gmp
tumor lysate
Online Access:https://www.mdpi.com/2076-393X/8/1/25

Internet

https://www.mdpi.com/2076-393X/8/1/25

Similar Items